Clinuvel Pharmaceuticals Limited · ASX:CUV
Clinuvel Pharmaceuticals — Corporate Update (October 2021)
8 slides from Clinuvel Pharmaceuticals's corporate update, Oct 25, 2021
Slide 1: CLINUVEL Investor Webinar
CLINUVEL Group ASX: CUV Level 1 ADR (Nasdaq Int’l Designation): CLVLY XETRA-DAX: UR9 clinuvel.com news.clinuvel.com CLINUVEL Investor Webinar Shareholder Questions Answered 25 October 2021 Moderated by Mr Malcolm Bull Head of Investor Relations with Dr Philippe Wolgen Managing Director
Slide 2: Legal Notice
Legal Notice This release contains forward-looking statements, which reflect the current the outsourced manufacturing of SCENESSE® which may lead to it being beliefs and expectations of CLINUVEL’s management. Statements may involve unable to supply its commercial markets and/or clinical trial progra
Slide 3: Key Events FY2021
Shareholder Questions Answered Key Events FY2021 1. Strong Financial Performance Revenues: 43% to A$48.5 million Net Profit (before tax): 123% to A$25.7 million EPS: 64% to A$0.50 2. Increased Access to SCENESSE®: Europe & US 3. Growth: Four Divisions 4. R&D Expansion 5. Start of Stroke Program; XP
Slide 4: CLINUVEL's Strategic Path
Shareholder Questions Answered CLINUVEL’s Strategic Path Multi-pronged Strategy Expansion 1. Afamelanotide in Multiple Indications 2. Portfolio of Melanocortins 3. Targeted Technology Translation CLINUVEL PHARMACEUTICALS 4 INVESTOR WEBINAR OCT 2021
Slide 5: Vitiligo
Shareholder Questions Answered Vitiligo 1. Viable Study Design (CUV104) 2. Meaningful Endpoints 3. Impact of Disease 4. Minimal Important Difference 5 CUV102 participant, image CLINUVEL PHARMACEUTICALS INVESTOR WEBINAR OCT 2021 courtesy of the investigator
Slide 6: Your Questions on New Indications
Shareholder Questions Answered Your Questions on New Indications What can we expect? CLINUVEL PHARMACEUTICALS 6 INVESTOR WEBINAR OCT 2021
Slide 7: Key Outputs 2022
Shareholder Questions Answered Key Outputs 2022 1. Expansion & Distribution SCENESSE® 2. Progress DNA Repair Program • XP Studies • Unattended Photodamage - OTC 3. Complete First Stroke Study (CUV801) 4. Vitiligo Program (CUV104) 5. New Indication Strategic Update III before AGM CLINUVEL PHARMACEUTI
Slide 8: Thank You
CLINUVEL Group ASX: CUV Level 1 ADR (Nasdaq Int’l Designation): CLVLY XETRA-DAX: UR9 clinuvel.com news.clinuvel.com Thank You For Your Attention Moderated by Mr Malcolm Bull Head of Investor Relations with Dr Philippe Wolgen Managing Director
CLINUVEL Pharmaceuticals — Corporate Update (October 2021) on 6ix